EDGAR·FLOW

NRX Pharmaceuticals, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q ▲ Likely positive significance 72/100
What the filing says
NRX Defense Systems, Inc. (subsidiary of NRx Pharmaceuticals) signed an 18-month DARPA 'other transaction' agreement (HR0011-26-3-E138) for $11,177,757 total value, with $6,681,753 currently obligated. The agreement funds a 240-patient randomized controlled trial combining ultra-accelerated transcranial magnetic stimulation (uaTMS) with NRX-101 (D-cycloserine + lurasidone) to treat treatment-resistant depression in military personnel. Milestone-based payments via pre-established schedule; NRX retains patent rights with DARPA receiving nonexclusive license; agreement commenced upon final signature (filed November 2026).
Why this rating

DARPA funding of $6.7M obligated (11.7% of company's $57.4M market cap) for pivotal trial is meaningful and advances FDA approval path for core asset NRX-101, but subject to trial success and milestone achievement.

Tradability signal
NO TRADE

No trade: positive news with only +0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.26% over 4 hrs, n=543). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.14 ▲ 0.01%
at our read · unknown
$2.14
+10 min · unknown
$2.24 ▲ 4.91%
+30 min · unknown
$2.31 ▲ 8.23%
+1 hr · unknown
$2.46 ▲ 15.01%
+4 hrs · unknown
$2.34 ▲ 9.40%

The stock had already moved -0.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ NRXP · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.